DDInter513 DDInter1763
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Dexamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Dexamethasone {u} (Compound) palliates {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Temsirolimus
Dexamethasone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Dexamethasone {u} (Compound) upregulates {v} (Gene) MYC
MYC {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Dexamethasone {u} (Compound) downregulates {v} (Gene) TCEA2
TCEA2 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Dexamethasone {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Dexamethasone {u} (Compound) upregulates {v} (Gene) RPP38
RPP38 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Dexamethasone {u} (Compound) downregulates {v} (Gene) RPS4Y1
RPS4Y1 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Dexamethasone {u} (Compound) causes {v} (Side Effect) Ecchymosis
Ecchymosis {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Dexamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Dexamethasone (Compound) palliates kidney cancer (Disease) and kidney cancer (Disease) is treated by Temsirolimus (Compound)
Dexamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Dexamethasone (Compound) upregulates MYC (Gene) and MYC (Gene) is upregulated by Temsirolimus (Compound)
Dexamethasone (Compound) downregulates TCEA2 (Gene) and TCEA2 (Gene) is upregulated by Temsirolimus (Compound)
Dexamethasone (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Temsirolimus (Compound)
Dexamethasone (Compound) upregulates RPP38 (Gene) and RPP38 (Gene) is downregulated by Temsirolimus (Compound)
Dexamethasone (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Temsirolimus (Compound)
Dexamethasone (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Temsirolimus (Compound)
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)